Trulieve Reports First Quarter 2025 Results Demonstrating Core Business Strength
"Strong margins and cash flow achieved in the first quarter clearly demonstrate our commitment to operational excellence," said Kim Rivers, Trulieve CEO. "With our loyal customer base, branded products, and efforts to drive cannabis reform, Trulieve stands out as an industry leader."
Currently operate 229 retail dispensaries and over four million square feet of cultivation and processing capacity in the United States.
4/20 holiday season units sold and traffic increased 20% and 9%, respectively versus last year.
*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
Opened six dispensaries in Maricopa, Arizona; Middleburg, North Miami Beach, and Palm Coast, Florida; and Columbus and Zanesville, Ohio. Relocated one dispensary to Lancaster, Pennsylvania.
Launched Onward, a premium, non-alcoholic THC beverage available for purchase by consumers 21 years and older at select retail locations in Florida or ordered via DrinkOnward.com for direct shipment to 36 states.
Rewards program members reached over 625,000 members as of March 31, 2025. Loyalty members accounted for 68% of transactions during the first quarter.
Generated cash flow from operations of $51 million and free cash flow of $34 million*.
Achieved adjusted EBITDA of $109 million*, or 37% of revenue, up 3% year over year.
Reported net loss attributable to common shareholders of $33 million. Adjusted net loss of $3 million* excludes non-recurring charges, asset impairments, disposals and discontinued operations.
Achieved gross margin of 62% versus 58% last year, with GAAP gross profit of $183 million.
Revenue of $298 million increased slightly year over year, with 95% of revenue from retail sales.
TALLAHASSEE, Fla., May 7, 2025 /CNW/ -- Trulieve Cannabis Corp . (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended March 31, 2025. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles unless otherwise indicated. Numbers may not sum perfectly due to rounding.
4/20 holiday season units sold and traffic increased 20% and 9%, respectively, year over year
Cash flow from operations of $51 million and free cash flow of $34 million*
Story Continues
Financial Highlights*
Results of Operations
For the Three Months Ended
(Figures in millions except per share data)
March 31,
2025
March 31,
2024
% Better
/
(Worse)
December 31,
2024
% Better
/
(Worse)
Revenue
$
298
$
298
— %
$
301
(1 %)
Gross profit
$
183
$
174
5 %
$
187
(2 %)
Gross margin %
62 %
58 %
62 %
Operating expenses
$
150
$
128
(17 %)
$
186
19 %
Operating expenses %
50 %
43 %
62 %
Net loss**
$
(33)
$
(23)
(42 %)
$
(60)
45 %
Net loss continuing operations
$
(32)
$
(23)
(37 %)
$
(60)
47 %
Adjusted net (loss) income
$
(3)
$
(10)
67 %
$
3
NMF
Basic and diluted shares outstanding
191
189
190
EPS continuing operations
$
(0.16)
$
(0.16)
(1 %)
$
(0.26)
37 %
Adjusted EPS
$
(0.02)
$
(0.05)
67 %
$
0.02
NMF
Adjusted EBITDA
$
109
$
106
3 %
$
111
(2 %)
Adjusted EBITDA Margin %
37 %
36 %
37 %
NMF - No Meaningful Figure
*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
**Net loss attributable to common shareholders which excludes non-controlling interest.
Conference Call
The Company will host a conference call and live audio webcast on May 7, 2025, at 8:30 A.M. Eastern time, to discuss its first quarter 2025 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.
North American toll free: 1-844-824-3830
Passcode: 4932405
International: 1-412-542-4136
Passcode: 4932405
A live audio webcast of the conference call will be available at:
Trulieve First Quarter 2025 Results Call
A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events
The Company's Form 10-Q for the quarter ended March 31, 2025, will be available on the SEC's website or at https://investors.trulieve.com/quarterly-results . The Company's Management Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on https://www.sedarplus.ca/landingpage/ and on its website at https://investors.trulieve.com/quarterly-results . This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.
Trulieve Cannabis Corp.
Condensed Consolidated Balance Sheets (Unaudited)
(in millions, except for share data)
March 31,
2025
December 31,
2024
ASSETS
Current Assets:
Cash and cash equivalents
$ 328.5
$ 238.8
Short-term investments
—
60.4
Restricted cash
0.9
0.9
Accounts receivable, net
10.3
8.3
Inventories
239.3
231.4
Income tax receivable
8.6
10.0
Prepaid expenses
24.2
23.0
Other current assets
32.3
26.2
Notes receivable - current portion, net
4.5
4.8
Assets associated with discontinued operations
0.9
0.9
Total current assets
649.4
604.6
Property and equipment, net
710.1
716.1
Right of use assets - operating, net
117.0
119.5
Right of use assets - finance, net
64.4
64.4
Intangible assets, net
848.8
859.5
Goodwill
483.9
483.9
Notes receivable, net
0.5
0.5
Other assets
11.5
19.8
Long-term assets associated with discontinued operations
2.0
2.0
TOTAL ASSETS
$ 2,887.6
$ 2,870.3
LIABILITIES
Current Liabilities:
Accounts payable and accrued liabilities
$ 91.1
$ 94.0
Deferred revenue
8.7
8.0
Notes payable - current portion
3.5
3.4
Operating lease liabilities - current portion
12.3
12.1
Finance lease liabilities - current portion
9.9
9.5
Construction finance liabilities - current portion
2.0
1.9
Contingencies
5.6
6.3
Liabilities associated with discontinued operations
3.4
3.1
Total current liabilities
136.7
138.5
Long-Term Liabilities:
Private placement notes, net
365.3
364.8
Notes payable, net
111.1
111.9
Operating lease liabilities
116.5
117.5
Finance lease liabilities
68.0
67.7
Construction finance liabilities
135.1
135.5
Deferred tax liabilities
191.9
196.5
Uncertain tax position liabilities
500.9
445.2
Other long-term liabilities
5.5
5.0
Long-term liabilities associated with discontinued operations
37.7
38.6
TOTAL LIABILITIES
$ 1,668.8
$ 1,621.2
SHAREHOLDERS' EQUITY
Common stock, no par value; unlimited shares authorized. 191,077,446 and
191,005,940 shares issued and outstanding as of March 31,
2025 and December 31, 2024, respectively.
$ —
$ —
Additional paid-in-capital
2,060.7
2,057.0
Accumulated deficit
(828.6)
(795.7)
Non-controlling interest
(13.2)
(12.3)
TOTAL SHAREHOLDERS' EQUITY
1,218.9
1,249.0
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$ 2,887.6
$ 2,870.3
Trulieve Cannabis Corp.
Condensed Consolidated Statements of Operations (Unaudited)
(in millions, except for share data)
Three Months Ended
March 31,
2025
2024
Revenue
$ 297.8
$ 297.6
Cost of goods sold
114.5
123.8
Gross profit
183.2
173.8
Expenses:
Selling, general, and administrative
118.8
101.3
Depreciation and amortization
29.3
27.8
Impairment and disposal of long-lived assets, net of (recoveries)
1.8
(1.4)
Total expenses
149.9
127.7
Income from operations
33.3
46.1
Other income (expense):
Interest expense, net
(16.3)
(14.7)
Interest income
3.1
3.3
Other income (expense), net
0.2
(2.7)
Total other expense, net
(13.0)
(14.2)
Income before provision for income taxes
20.3
31.9
Provision for income taxes
52.5
55.4
Net loss from continuing operations
(32.1)
(23.5)
Net loss from discontinued operations, net of $0 tax benefit
(1.6)
(1.4)
Net loss
(33.8)
(24.8)
Less: net loss attributable to non-controlling interest from continuing operations
(0.9)
(1.8)
Net loss attributable to common shareholders
$ (32.9)
$ (23.1)
Earnings Per Share
Net loss per share - Continuing operations:
Basic and diluted
$ (0.16)
$ (0.16)
Net loss per share - Discontinued operations:
Basic and diluted
$ (0.01)
$ (0.01)
Weighted average number of common shares used in computing net loss per share:
Basic and diluted
191.1
189.5
Trulieve Cannabis Corp.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in millions)
Three Months Ended
March 31,
2025
2024
Cash flows from operating activities
Net loss
$ (33.8)
$ (24.8)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization
29.3
27.8
Depreciation included in cost of goods sold
13.9
13.5
Impairment and disposal of long-lived assets, net of (recoveries)
1.8
(1.4)
Share-based compensation
3.9
5.2
Deferred income taxes
(4.7)
10.0
Other non-cash changes
5.0
6.1
Changes in operating assets and liabilities:
Inventories
(7.9)
3.5
Accounts receivable
(2.6)
1.5
Other assets
(8.4)
(1.4)
Accounts payable and accrued liabilities
(0.2)
1.0
Income tax receivable / payable
1.4
2.7
Other liabilities
(2.7)
(3.6)
Uncertain tax position liabilities
55.7
97.6
Proceeds received from insurance for operating expenses
—
1.5
Net cash provided by operating activities
50.7
139.2
Cash flows from investing activities
Purchases of property and equipment
(16.9)
(15.5)
Purchases of internal use software
(3.9)
(5.0)
Maturities of short-term investments
60.4
—
Other proceeds
4.0
1.5
Other purchases and payments
(0.2)
—
Net cash provided by (used in) investing activities
43.4
(19.0)
Cash flows from financing activities
Payments on long-term borrowings
(1.9)
(1.7)
Payments for taxes related to net share settlement of equity awards
(0.2)
—
Proceeds from equity exercises
—
0.2
Other payments and distributions
(2.4)
(3.0)
Other proceeds
—
3.0
Net cash used in financing activities
(4.5)
(1.6)
Net increase in cash, cash equivalents, and restricted cash
89.6
118.6
Cash, cash equivalents, and restricted cash, beginning of period
239.7
208.0
Cash and cash equivalents of discontinued operations, beginning of period
—
0.3
Less: cash and cash equivalents of discontinued operations, end of period
—
—
Cash, cash equivalents, and restricted cash, end of period
$ 329.4
$ 326.9
The consolidated statements of cash flows include continuing operations and discontinued operations for the periods presented.
Non-GAAP Financial Measures (Unaudited)
In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, adjusted net (loss) income, adjusted net (loss) income per diluted share, and free cash flow.
The Company calculates EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization; adjusted EBITDA as net income (loss) before net interest expense, interest income, income tax expense, depreciation and amortization and also excludes certain extraordinary items; EBITDA margin as EBITDA as % of revenue; adjusted EBITDA margin as adjusted EBITDA as % of revenue; adjusted net income (loss) as net income (loss) less certain extraordinary items; adjusted EPS as adjusted net income (loss) divided by basic and diluted shares outstanding; and free cash flow as cash flow from operations less capital expenditures.
Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures are not, and should not be considered as, measures of liquidity. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.
Reconciliation of Non-GAAP EBITDA and Adjusted EBITDA (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP EBITDA and Adjusted EBITDA for each of the periods presented:
(Amounts expressed in millions of United States dollars)
Three Months Ended
March 31,
2025
March 31,
2024
December
31, 2024
Net loss attributable to common shareholders
$
(32.9)
$
(23.1)
$
(59.8)
Add (deduct) impact of:
Interest expense, net
$
16.3
$
14.7
$
14.6
Interest income
$
(3.1)
$
(3.3)
$
(3.2)
Provision for income taxes
$
52.5
$
55.4
$
47.6
Depreciation and amortization
$
29.3
$
27.8
$
28.6
Depreciation included in cost of goods sold
$
13.9
$
13.5
$
13.5
EBITDA (Non-GAAP)
$
76.0
$
85.0
$
41.3
EBITDA Margin (Non-GAAP)
26 %
29 %
14 %
Impairment and disposal of long-lived assets, net of (recoveries)
$
1.8
$
(1.4)
$
(0.9)
Campaign and political contributions
$
23.0
$
9.2
$
54.8
Acquisition, transaction, and other non-recurring costs
$
3.1
$
3.7
$
7.6
Share-based compensation
$
3.9
$
5.2
$
4.6
Other (income) expense, net
$
(0.2)
$
2.7
$
2.8
Discontinued operations, net of tax, attributable to common shareholders
$
1.6
$
1.4
$
1.1
Adjusted EBITDA (Non-GAAP)
$
109.2
$
105.8
$
111.4
Adjusted EBITDA Margin (Non-GAAP)
37 %
36 %
37 %
Reconciliation of Non-GAAP Adjusted Net (Loss) Income (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders to non-GAAP adjusted net (loss) income, for each of the periods presented:
For the Three Months Ended
(Amounts expressed in millions of United States dollars)
March 31,
2025
March 31,
2024
December
31, 2024
Net loss attributable to common shareholders
$
(32.9)
$
(23.1)
$
(59.8)
Net loss from discontinued operations, net of tax, attributable to common shareholders
$
1.6
$
1.4
$
1.1
Adjustment of formerly redeemable non-controlling interest to maximum redemption value
$
—
$
(8.8)
$
9.0
Net loss from continuing operations available to common shareholders
$
(31.2)
$
(30.6)
$
(49.7)
Add (deduct) impact of:
Adjustment of formerly redeemable non-controlling interest to maximum redemption value
$
—
$
8.8
$
(9.0)
Impairment and disposal of long-lived assets, net of (recoveries)
$
1.8
$
(1.4)
$
(0.9)
Campaign and political contributions
$
23.0
$
9.2
$
54.8
Acquisition, transaction, and other non-recurring costs
$
3.1
$
3.7
$
7.6
Adjusted net (loss) income (Non-GAAP)
$
(3.4)
$
(10.2)
$
2.9
Reconciliation of Non-GAAP Adjusted Net (Loss) Income Per Diluted Share (Unaudited)
The following table presents a reconciliation of GAAP net loss attributable to common shareholders per share to non-GAAP adjusted net (loss) income per diluted share, for each of the periods presented:
For the Three Months Ended
(Amounts expressed are per share except for shares which are in millions)
March 31,
2025
March 31,
2024
December
31, 2024
Net loss attributable to common shareholders
$
(0.17)
$
(0.12)
$
(0.31)
Net loss from discontinued operations, net of tax, attributable to common shareholders
$
0.01
$
0.01
$
0.01
Adjustment of formerly redeemable non-controlling interest to maximum redemption value
$
—
$
(0.05)
$
0.05
Net loss from continuing operations available to common shareholders
$
(0.16)
$
(0.16)
$
(0.26)
Add (deduct) impact of:
Adjustment of formerly redeemable non-controlling interest to maximum redemption value
$
—
$
0.05
$
(0.05)
Impairment and disposal of long-lived assets, net of (recoveries)
$
0.01
$
(0.01)
$
(0.00)
Campaign and political contributions
$
0.12
$
0.05
$
0.29
Acquisition, transaction, and other non-recurring costs
$
0.02
$
0.02
$
0.04
Adjusted net (loss) income (Non-GAAP)
$
(0.02)
$
(0.05)
$
0.02
Basic and diluted shares outstanding
191.1
189.5
190.0
Reconciliation of Non-GAAP Free Cash Flow (Unaudited)
The following table presents a reconciliation of GAAP cash flow from operating activities to non-GAAP free cash flow, for each of the periods presented:
For the Three Months Ended
(Amounts expressed in millions of United States dollars)
March 31,
2025
March 31,
2024
December
31, 2024
Cash flow from operating activities
$
50.7
$
139.2
$
30.7
Payments for property and equipment
$
(16.9)
$
(15.5)
$
(42.7)
Free cash flow (Non-GAAP)
$
33.9
$
123.7
$
(12.0)
Forward-Looking Statements
This news release includes forward-looking information and statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation (collectively herein referred to as "forward-looking statements"). These forward-looking statements relate to the Company's expectations or forecasts of business, operations, financial performance, cash flows, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding the Company's 2025 objectives, growth opportunities, and positioning for the future. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and in our periodic reports subsequently filed with the United States Securities and Exchange Commission and in the Company's filings on https://www.sedarplus.ca/landingpage/ . Although the Company believes that any forward-looking statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such statements, there can be no assurance that any such forward-looking statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking statements. Any forward-looking statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking statements herein, whether as a result of new information, future events or results, or otherwise.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve
X: @Trulieve
Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck, APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-reports-first-quarter-2025-results-demonstrating-core-business-strength-302447866.html
SOURCE Trulieve Cannabis Corp.
Cision
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/07/c2643.html
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
DocuSign: Questions Around Growth Remain
DocuSign posted revenue and earnings growth, beating estimates. The company's free cash flow fell slightly, and its full-year forecast underwhelmed investors. DocuSign has steadied itself, but investors are not yet seeing clear answers to the question of how growth can accelerate from here. 10 stocks we like better than Docusign › Here's our initial take on DocuSign's (NASDAQ: DOCU) financial report. Metric Q1 FY25 Q1 FY26 Change vs. Expectations Revenue $709.6 million $763.7 million 8% Beat Earnings per share (adjusted) $0.82 $0.90 10% Beat Non-GAAP billings $709.5 million $739.6 million 4% n/a Free cash flow $232.1 million $227.8 million -2% n/a There was a lot to like about DocuSign's latest quarter. Revenue and adjusted earnings per share were up 8% and 10%, respectively, topping Wall Street expectations. GAAP (generally accepted accounting principles) gross margin came in at 79.4%, up 5 basis points from a year ago, and the company posted solid free cash flow of $227.8 million. DocuSign also surpassed the 10,000 Intelligent Agreement Management customer threshold during the period. Billings rose 4% in the quarter, but DocuSign warned that it expects momentum to fade as the year goes on. For fiscal 2026, DocuSign is now forecasting total billings of $3.285 billion and $3.39 billion, down from its prior guidance for $3.3 billion to $3.4 billion. The billings revision, though slight, highlights the biggest challenge facing DocuSign right now. The business is healthy and profitable, but investors are worried about where growth will come from. The company is forecasting full-year fiscal 2026 revenue of $3.15 billion to $3.16 billion, which, at the midpoint, would represent just a 5% gain from last year's $2.98 billion in total revenue. DocuSign is putting its cash to work for investors, announcing a new $1 billion repurchase program. But with the company's share count up nearly 6% in just the last three years, much of the buyback would only serve to offset share-based compensation that has added to the float. Investors were more focused on the look ahead than the results. DocuSign shares were down 15% in aftermarket trading following the release but ahead of the company's call with investors. CEO Allan Thygesen, who has been on the job since October 2022, called the results "an important quarter for Docusign's long-term transformation," highlighting the company's "ambitious product roadmap." Expect investors to press Thygesen for specifics about how the transformation is going and when it will translate into real, sustained growth. DocuSign invented its category and continues to hold strong in its core business, even up against competition from Adobe (NASDAQ: ADBE) and Microsoft (NASDAQ: MSFT), which can incorporate e-signatures into broader offerings. But Wall Street is forward-looking. Shares of DocuSign are up nearly 75% over the past year as an initial response to Thygesen's turnaround ambitions. Until investors gain confidence that DocuSign has found a formula to expand its core offering and generate significant revenue growth, the stock could face limits on its ability to accelerate higher from here. Full earnings report Investor relations page Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adobe, Docusign, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. DocuSign: Questions Around Growth Remain was originally published by The Motley Fool Sign in to access your portfolio


Forbes
2 hours ago
- Forbes
Republican-Led House Committee Passes Bill To Ban Hemp Products With THC
Delta-8, which contains tetrahydrocannabinol, which the FDA says has not been evaluated or approved ... More "for safe use and may be marketed in ways that put the public health at risk," according to the federal government website, is being marketed in the mid-Atlantic area, including in stores like this one in downtown Baltimore on May 12, 2022. (Karl Merton Ferron/Baltimore Sun/Tribune News Service via Getty Images) A Republican-led House committee has approved a spending bill that includes a measure to ban all hemp products with THC nationwide, a move that could upend the entire U.S. hemp industry. The House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies approved on June 5 the fiscal year 2026 spending proposal in a 9–7 vote, sending it to the full Committee. The bill covers a wide range of issues, including hemp. One section of the bill would, in fact, redefine hemp under federal law to ban cannabis products that contain any 'quantifiable' amount of THC or any other cannabinoids with similar effects or marketed as such on people or animals. The language used to define hemp is similar to an amendment to the new Farm Bill that was approved last year by the U.S. House Agriculture Committee. That amendment, proposed by Republican Rep. Mary Miller of Illinois, aimed to shut down the gray market for intoxicating hemp-derived products like delta-8 THC by closing the loophole created by the 2018 Farm Bill. However, it wasn't ultimately enacted by the last Congress. Still, the goal remains the same: to close the hemp loophole that's led to a flood of unregulated, intoxicating products being sold online and at gas stations nationwide, as emphasized by the Committee's press release. Specifically, the bill would redefine hemp to exclude any finished hemp products that contain cannabinoids not naturally produced by the plant, cannabinoids that are naturally occurring but were made or altered outside the plant, any quantifiable amount of THC or THCA, or other cannabinoids with similar effects on people or animals. It would also give the U.S. Secretary of Health and Human Services the authority to decide what counts as a 'quantifiable amount' of THC or similar cannabinoids. At the same time, industrial hemp grown for industrial purposes would be treated differently, signaling a significant change to the current hemp definition, which, under the 2018 Farm Bill, meant plants with no more than 0.3% THC by dry weight before harvest. Paula Savchenko, Esq., founding partner of Cannacore Group and PS Law Group, said that the proposed legislation, while maintaining the legal status of industrial hemp for purposes such as fiber, grain, and certain edible products intended for human consumption, 'would effectively ban the vast majority of hemp-derived cannabinoids,' adding that 'its future will depend on further deliberations in Congress and potential revisions during the legislative process.' The bill is now set for discussion and possible amendments before the full House Appropriations Committee on June 11. Hemp was legalized nationwide in 2018 with the Farm Bill, which set a limit of 0.3% THC for cannabis grown for industrial purposes. This was meant to keep hemp products from having the intoxicating effects of recreational cannabis, which remains illegal at the federal level. But the rise of hemp cannabinoid extraction opened the door to products containing intoxicating hemp-derived cannabinoids like delta-8 THC, which users say produces a similar high to traditional cannabis. These products are now widely sold in stores, gas stations, and online across the country. A 2022 study found they're especially popular in states that haven't legalized recreational cannabis. The gray legal status of hemp products with THC has stirred concern over both safety and regulation. Though technically legal under federal law, their effects closely mirror those of recreational cannabis, which is still banned at the federal level. That disconnect has left states scrambling, as businesses capitalize on a loophole in the Farm Bill to produce and sell these products with little oversight. The boom of hemp products with THC has, in fact, fueled what's expected to become a multi-billion dollar industry. But it has also pushed many states to step in with their own rules, some opting to regulate, others choosing outright bans. States like Minnesota, Iowa, and Kentucky have regulated products like delta-8 THC, while New York, Delaware, and Colorado, among other states, have banned them altogether. In recent months, Texas lawmakers have been trying to ban hemp products with THC. While states continue crafting their own rules on hemp products with THC, this federal bill could shut the entire market down by banning all such products nationwide and closing the loophole that allowed hemp products with THC to be sold legally under the 2018 Farm Bill. The move, however, has sparked a backlash from hemp industry associations. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said in a press statement that the group is 'deeply disappointed' with Rep. Andy Harris, Republican of Maryland, who chairs the House Agriculture Appropriations Subcommittee. Miller accused Harris of trying to 'shoehorn a farmer-crushing, job-killing hemp ban into a spending bill,' and expressed hope that the effort will fail, as it has in the past. Meanwhile, the National Cannabis Industry Association (NCIA) is calling on lawmakers to reject proposed language that would redefine hemp in a way that bans any product with a 'quantifiable' amount of THC. The group warns that the ban on hemp products with THC would devastate legal businesses and drive demand toward the unregulated black market.
Yahoo
3 hours ago
- Yahoo
Why Docusign Stock Got Devastated Today
Docusign doubled its GAAP profits and beat earnings last night -- but free cash flow delined. Growth is slowing at the e-signatures stock, and investors are nervous. 10 stocks we like better than Docusign › Docusign (NASDAQ: DOCU) stock plunged 19.3% through 11:11 a.m. ET this morning despite "beating earnings" on both top and bottom lines last night. Heading into the company's fiscal Q1 2026, analysts forecast the e-signatures company would earn $0.81 per share on just under $750 million in sales. In fact, Docusign earned $0.90 per share, "adjusted," on sales of nearly $764 million. Sales grew 8% year over year, but billings were up only 4% -- which may foreshadow a slowdown in growth ahead. Gross profit margins, on the other hand, improved 50 basis points to 79.4%. And diluted earnings as calculated according to generally accepted accounting principles (GAAP) more than doubled to $0.34 per share. Not quite as good as "$0.90," but still a big improvement. All this being said, Docusign's free cash flow belied the growth in both sales and earnings. FCF for the quarter was only $227.8 million in Q1, versus $232.1 million a year ago. It didn't double. It didn't grow even 8%. It... went down. Should this worry investors? Perhaps. Docusign's Q2 guidance sees sales growth slowing to 6%, $779 million in revenue or thereabouts. Growth for the full year is likewise forecast at about 6%, $3.15 billion or $3.16 billion in annual sales. That's not a lot of growth for a supposed growth stock, and reinforces the impression we get from slow billings growth. That said, Docusign stock sells for an unchallenging valuation of only 16.6 times trailing FCF -- cheaper than that when you factor in net cash on the balance sheet. If Docusign can just find a way to goose its growth rate again, this stock could still be a buy. Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Docusign. The Motley Fool has a disclosure policy. Why Docusign Stock Got Devastated Today was originally published by The Motley Fool